2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal Of Infectious Diseases 2017, 216: 798-807. PMID: 29029344, PMCID: PMC5853503, DOI: 10.1093/infdis/jix349.Peer-Reviewed Original ResearchConceptsNational HIV/AIDS StrategyIncremental cost-effectiveness ratioHuman immunodeficiency virusCost-effectiveness ratioUS National HIV/AIDS StrategyHIV/AIDS StrategyAntiretroviral therapy costsSubstantial clinical benefitHigh HIV prevalenceGeneral US populationYears of lifeVirologic suppressionViral suppressionClinical outcomesAdherence interventionsClinical benefitHIV prevalenceHIV transmissionImmunodeficiency virusMSM populationAIDS StrategyTherapy costsTreatment targetsUS populationBlack men
2009
HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies
April MD, Walensky RP, Chang Y, Pitt J, Freedberg KA, Losina E, Paltiel AD, Wood R. HIV Testing Rates and Outcomes in a South African Community, 2001-2006: Implications for Expanded Screening Policies. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 51: 310-316. PMID: 19582895, PMCID: PMC3209660, DOI: 10.1097/qai.0b013e3181a248e6.Peer-Reviewed Original ResearchConceptsART initiation ratesHIV testing ratesAntiretroviral treatmentTesting ratesHIV testingWorld Health Organization stageProvider-initiated testingFirst-time testersWorld Health Organization recommendationsMonths of eligibilityHigh-prevalence populationsHealth care facilitiesProportion of clientsMedian CD4Testing registersAnnual incidenceHIV servicesLate diagnosisPrevalence populationsTreatment trendsCare facilitiesStage distributionScreening policiesPatient recordsPopulation testing
2002
Task Force #2—the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, Paltiel AD. Task Force #2—the cost of prevention: can we afford it? Can we afford not to do it? Journal Of The American College Of Cardiology 2002, 40: 603-615. PMID: 12204490, DOI: 10.1016/s0735-1097(02)02083-1.Peer-Reviewed Original Research
1997
The Cost-Effectiveness of HIV Testing
Paltiel AD, Kaplan EH. The Cost-Effectiveness of HIV Testing. Medical Decision Making 1997, 17: 490-495. PMID: 9343808, DOI: 10.1177/0272989x9701700415.Peer-Reviewed Original ResearchConceptsNational surveillance surveyCost-effectiveness estimatesVoluntary HIVHIV testingSeroprevalence studySurveillance SurveyUninfected peopleTesting ratesUninfected individualsHIVInfectionDifferential participationPrevalenceLittle riskParticipation ratesMagnitude of resultsSeronegativesCost drivers